Press Releases

and/or
565 News Releases found
Ross Levine
Foundation Medicine and Memorial Sloan Kettering Cancer Center today announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers.
Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan Kettering Cancer Center and other centers within The Cancer Genome Atlas Research Network.
The ESK1 monoclonal antibody was engineered to recognize WT1 peptides brought to the surface of cancer cells.
Scientists from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics have collaborated to create the new human monoclonal antibody, which targets a protein associated with many types of cancer and is of great interest to cancer researchers.
In this new expanded role, Avice Meehan will streamline communications across the Center and lead both Memorial Sloan Kettering’s Public Affairs and Marketing endeavors.
Memorial Sloan Kettering Cancer Center announces the appointments of medical oncologist Anas Younes, surgical pathologist David S. Kimstra, surgeon Julio Garcia-Aguilar, and radiologist Wolfgang Weber.
The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan Kettering Cancer Center.
Westchester Medical Center today announced the opening of its new 5,300-square-foot outpatient Infusion Center, ushering in a new partnership with Memorial Sloan Kettering Cancer Center, whose staff will provide outpatient cancer care and infusion services.
IBM, WellPoint, Inc., and Memorial Sloan Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence-based medicine.
Pictured: Paul Sabbatini
Memorial Sloan Kettering Cancer Center has announced the appointment of medical oncologist Paul Sabbatini to the new position of Deputy Physician-in-Chief for Clinical Research.
A new pancreatic cancer research center has been created at Memorial Sloan Kettering Cancer Center (MSKCC). The ambitious initiative was established with an initial commitment of $10 million from MSKCC Board member David M. Rubenstein.